CytomX Therapeutics 주식 (NASDAQ: CTMX)

에 대한 최신 뉴스 CytomX Therapeutics (NASDAQ:CTMX) 주식

CYTOMX THERAPEUTICS INC

CytomX Therapeutics

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) reported quarterly losses of $(3.12) per share which missed the analyst consensus estimate of $(1.71) by 82.46 percent. This is a 11.43 percent decrease over losses of $(2.80) per share from the same period last year. The company reported quarterly sales of $40.53 million which missed the analyst consensus estimate of $53.55 million by 24.31 percent. This is a 25.18 percent decrease over sales of $54.17 million the same period last year.

Earnings

Earnings Misses

News

HYFM

Hydrofarm Holdings Group Q1 EPS $(3.12) Misses $(1.71) Estimate, Sales $40.53M Miss $53.55M Estimate

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) Q1 expected to be below $0.02 vs $(0.14) Est..

Guidance

Under Armour Q1  expected to be below $0.02 vs $(0.14) Est

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) is looking for Q1 Adj EPS of $0.01-$0.03 vs $(0.08) analyst estimate. sees sales of $1.125 billion-$1.137 billion vs $1.17 billion analyst estimate.

Under Armour Sees Q1 Adj EPS $0.01-$0.03 vs $(0.08) Est; Sees Sales $1.125B-$1.137B vs $1.17B Est

Earnings Beats

CYBR

CyberArk Software Q1 Adj. EPS $0.98 Beats $0.79 Estimate, Sales $317.60M Beat $305.23M Estimate

Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 128.57 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $36.84 million which beat the analyst consensus estimate of $32.76 million by 12.45 percent. This is a 2.07 percent decrease over sales of $37.62 million the same period last year.

BWEN

Broadwind Q1 EPS $(0.02) Beats $(0.04) Estimate, Sales $36.84M Beat $32.76M Estimate

Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) sees Q2 sales of $120.000 million-$123.000 million vs $119.01 million analyst estimate.

CAMT

Camtek Sees Q2 Sales $120.000M-$123.000M vs $119.01M Est

Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 73.68 percent increase over losses of $(0.38) per share from the same period last year.

ITRM

Iterum Therapeutics Q1 Adj. EPS $(0.10) Beats $(0.14) Estimate

Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11.11 percent. This is a 92 percent decrease over losses of $(0.25) per share from the same period last year.

ABOS

Acumen Pharmaceuticals Q1 GAAP EPS $(0.48) Beats $(0.54) Estimate

Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.77 by 2.6 percent. This is a 23.44 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $118.60 million which missed the analyst consensus estimate of $119.28 million by 0.57 percent. This is a 22.14 percent increase over sales of $97.10 million the same period last year.

Camtek Q1 Adj. EPS $0.79 Beats $0.77 Estimate, Sales $118.60M Miss $119.28M Estimate

Needham analyst Quinn Bolton reiterates MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on MagnaChip Semiconductor, Maintains $6 Price Target

Full Year 2025 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in millions, except per share amounts) (unaudited)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,710 - $1,734</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$463 - $478</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.21 - $2.51</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

PSFE

Paysafe Affirms FY2025 Adj EPS Guidance Of $2.21-$2.51 Vs $2.95 Est; Narrows FY2025 Sales Guidance Of $1.71B-$1.73B Vs $1.83B Est

Barclays analyst Julian Mitchell upgrades Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raises the price target from $69 to $90.

Upgrades

Barclays Upgrades Stanley Black & Decker to Overweight, Raises Price Target to $90

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion by 1.47 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.16B Estimate

Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.41 by 17.07 percent. This is a 40.35 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $401.00 million which missed the analyst consensus estimate of $404.56 million by 0.88 percent. This is a 4.01 percent decrease over sales of $417.74 million the same period last year.

Paysafe Q1 Adj. EPS $0.34 Misses $0.41 Estimate, Sales $401.00M Miss $404.56M Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.17 billion by 1.23 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.17B Estimate

Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) reported quarterly sales of $63.50 million which beat the analyst consensus estimate of $62.80 million by 1.11 percent. This is a 0.35 percent decrease over sales of $63.73 million the same period last year.

Endeavour Silver Q1 Sales $63.50M Beat $62.80M Estimate

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and lowers the price target from $5 to $0.39.

Downgrades

AFMD

Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) reported $32.55 million in sales this quarter. This is a 46.30 percent increase over sales of $22.25 million the same period last year.

BETR

Better Home & Finance Q1 Sales $32.55M Up From $22.25M YoY, Adj. Net loss $46.18M Down From $42.83M YoY

Benchmark analyst Cody Acree maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

INDI

Benchmark Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

Press Releases

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Health Care

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

Comments

CytomX Therapeutics

뉴스

에 대한 최신 뉴스 CytomX Therapeutics (NASDAQ:CTMX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌